Sun Y. Oh
Experienced in Large-Cell Lung Carcinoma

Dr. Sun Y. Oh

Oncology
Montefiore Einstein
Montefiore Medical Center
111 East 210th Street, 
Bronx, NY 
Offers Telehealth

Experienced in Large-Cell Lung Carcinoma
Montefiore Einstein
Montefiore Medical Center
111 East 210th Street, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sun Young Oh, MD, is an Oncologist and Assistant Professor, Oncology and Medicine at Montefiore Einstein. Her clinical focus is on medical oncology and the systemic treatment of breast cancer.

Dr. Oh is rated as an Experienced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Ewha Women's University
Residency
Jacobi Medical Center
Specialties
Oncology
Licenses
Internal Medicine in NY
Fellowships
Tufts New England Medical Center
Hospital Affiliations
Montefiore Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Archcare
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
The Wellness Plan Medical Centers
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Montefiore Medical Center
111 East 210th Street, Bronx, NY 10461
Call: 718-920-4057
Other Locations
Montefiore Einstein Comprehensive Cancer Center - Montefiore Medical Park
1695 Eastchester Road, Bronx, NY 10461
Call: 718-405-8505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Alisertib, Fulvestrant
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
View 5 Less Clinical Trials

30 Total Publications

Trends in Incidence of Invasive Lobular Carcinoma of the Breast by Race: Patterns by Age, Cancer Stage, and Socioeconomic Factors in the United States, 1992-2019.
Trends in Incidence of Invasive Lobular Carcinoma of the Breast by Race: Patterns by Age, Cancer Stage, and Socioeconomic Factors in the United States, 1992-2019.
Journal: Clinical breast cancer
Published: October 03, 2024
View All 30 Publications
Similar Doctors
Distinguished in Large-Cell Lung Carcinoma
Dr. Harry D. Harper
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Harry D. Harper
Oncology

HMH - John Theurer Cancer Center - Hackensack

92 2nd Street, 
Hackensack, NJ 
 (8.6 miles away)
551-996-5087
Languages Spoken:
English
See accepted insurances

Harry Harper is an Oncologist in Hackensack, New Jersey. Dr. Harper is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Tissue Biopsy.

Distinguished in Large-Cell Lung Carcinoma
Dr. Mark M. Awad
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Mark M. Awad
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (8.6 miles away)
212-639-2000
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Awad is an Oncologist in New York, New York. Dr. Awad has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Large-Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Awad is currently accepting new patients.

Distinguished in Large-Cell Lung Carcinoma
Dr. Mark G. Kris
Oncology
Distinguished in Large-Cell Lung Carcinoma
Dr. Mark G. Kris
Oncology

Memorial Solid Tumor Group

353 E 68th St, 
New York, NY 
 (8.9 miles away)
646-422-4300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Kris is an Oncologist in New York, New York. Dr. Kris is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC).

VIEW MORE LARGE-CELL LUNG CARCINOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oh's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Oh is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Oh is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Oh is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Inflammatory Breast Cancer
      Dr. Oh is
      Advanced
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Experienced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Oh is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer in Men
      Dr. Oh is
      Experienced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Chronic Inflammatory Demyelinating Polyneuropathy
      Dr. Oh is
      Experienced
      . Learn about Chronic Inflammatory Demyelinating Polyneuropathy.
      See more Chronic Inflammatory Demyelinating Polyneuropathy experts
    • Colorectal Cancer
      Dr. Oh is
      Experienced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Discoid Lupus Erythematosus (DLE)
      Dr. Oh is
      Experienced
      . Learn about Discoid Lupus Erythematosus (DLE).
      See more Discoid Lupus Erythematosus (DLE) experts
    • EGFR Positive Lung Cancer
      Dr. Oh is
      Experienced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.